Age-related macular degeneration is a leading cause of blindness and affects over 196 million people worldwide. Despite its prevalence, very little is known about the causes or mechanisms of this ...

An estimated 80 percent of patients with the wet form of macular degeneration are diagnosed too late for effective treatment. Now, there's a new computerized test that can detect it earlier than ever ...

(National) February 6, 2006 - Many don't realize they have age-related macular degeneration until the damage is already done to their sight. But a new test may detect early signs of the sight-robbing ...

An Amsler grid, also known as an Amsler grid test, is a tool you can use at home to test your eyes for vision problems. It’s commonly used to test for signs of age-related macular degeneration (AMD).

A new artificial intelligence system — iPredict.Health from iHealthScreen — can accurately screen patients for age-related macular degeneration (AMD), results from a prospective clinical trial suggest ...

—The findings about the diagnostic accuracy of the Amsler grid test for early detection of neovascular age-related macular degeneration suggest that the procedure will not replace regular ophthalmic ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The company is preparing to launch a non-invasive genetic ...

Assessment of visual function by testing for visual acuity, dark adaptation, contrast sensitivity and evaluation of retinal sensitivity by microperimetry can indicate different stages of disease ...

Cynthia Owsley PhD and Christine Curcio PhD (UAB) lead the Alabama Study on Early Age-related Macular Degeneration (ALSTAR2). This NEI-funded project prospectively assesses >500 persons over 3 years ...

Visible Genomics has launched a set of noninvasive genetic tests aimed at assessing the overall risk of developing age-related macular degeneration (AMD) or progressing with the disease. AMD is a ...

A phase 2 clinical trial is underway at Columbia University and NewYork-Presbyterian to test an investigational gene therapy for dry age-related macular degeneration, a progressive, chronic eye ...